National Institute on Aging
31 Center Drive, MSC 2292
Building 31, Room 5C27
67 articles about National Institute on Aging
Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the NIA-sponsored CLARiTI Trial
Meilleur Technologies, Inc. today announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).
CHA Hollywood Presbyterian to Participate in $40 Million Study of Alzheimer's Disease in Persons of Korean, Vietnamese, and Chinese Ancestry
CHA Hollywood Presbyterian Medical Center is proud to announce its participation in a prestigious $40.5 million, multisite study funded by a grant from the National Institute on Aging, part of the National Institutes of Health, for the development of the Asian Cohort for Alzheimer’s Disease.
Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease
Praetego Inc is pleased to announce a $2.5M STTR award from the National Institute of Aging.
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
Oligomerix, Inc. announced an award of $2.49 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.
NIH researchers found that symptomatic herpes viruses were associated with neurological symptoms, but there was no evidence that herpes viruses are linked to Alzheimer’s disease.
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer's patients.
LifeBio Secures Second National Institute on Aging Grant; Research Will Use Artificial Intelligence as a Possible Diagnostic Tool for Alzheimer's
LifeBio announced its second National Institute on Aging (NIA) Small Business Innovation Research (SBIR) grant of $448,462 to focus on the Alzheimer's disease population.
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer's. Know more about it here.
Feinstein Institutes Receives $1.7M Grant to Study Behavior Change Science, Promote Exercise in Older Adults
Only half of the adults in the United States get the exercise they need to help reduce and prevent chronic diseases.
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Researchers with the National Institute on Aging published research of a gene variant, APO3 Christchurch (APOE3ch), that appears to confer resistance to Alzheimer’s disease.
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer's, Stem cell pioneer Bill Skarnes joins advisory board
Federal grant from the National Institute on Aging will fund a collaborative research incubator to support trials across the nation aimed at improving care for people with dementia